Description

Product details

Eligolux200 contains 200 mg of elagolix per tablet and is manufactured by Steris Healthcare Pvt Ltd in India as a prescription medication in packs of 3x10 tablets. Elagolix acts as a potent gonadotropin-releasing hormone (GnRH) receptor antagonist, binding competitively to GnRH receptors in the pituitary gland to rapidly reduce estrogen and progesterone levels without the initial flare- up seen in agonists. This mechanism starves endometrial-like tissue outside the uterus of hormonal stimulation, shrinking lesions and easing inflammation. Administer Eligolux200 orally, swallowed whole with water, with or without food, typically starting within 7 days of menstrual onset. Standard dosing for severe cases involves 200mg twice daily for up to 6 months, or 150mg once daily extended to 24 months, adjusted by physicians based on tolerance and response. Store in a cool, dry place away from moisture and light, keeping out of children's reach. Primary Uses Eligolux200 targets moderate to severe endometriosis-associated pain, including dysmenorrhea (painful periods), nonmenstrual pelvic pain, and dyspareunia (painful intercourse). Endometriosis affects millions globally, causing tissue similar to the uterine lining to grow ectopically, leading to chronic inflammation, adhesions, and scarring. By dosing flexibly, Eligolux200 suits patients needing stronger suppression for intense symptoms, reducing reliance on opioids or surgery. Clinical trials like Elaris EM-I and EM-II showed 75% dysmenorrhea reduction and 50-60% nonmenstrual pain relief at 6-12 months. It also curbs heavy menstrual bleeding in uterine fibroids, offering dual benefits for overlapping conditions. Physicians prescribe it when first-line NSAIDs or oral contraceptives fail, prioritizing non-invasive symptom control. ​ Key Benefits Eligolix in Eligolux200 delivers rapid pain relief, with significant improvements in daily pain scales within 3 months versus placebo. Women report 47% better composite pelvic pain scores, enhancing daily activities, work productivity, and intimacy. Quality-of-life metrics improve consistently over 24 weeks, including reduced fatigue and better emotional well-being. ​ Unlike injectables, its oral form and dose-dependent estrogen suppression allow titration—lower doses minimize hypoestrogenic effects while higher 200mg dosing tackles severe pain. Studies confirm amenorrhea in 25% of users early on, slashing bleeding days by up to 50%. Long-term data up to 12 months with add-back therapy sustains efficacy, preserving bone health better than monotherapy. Patients regain control, avoiding invasive laparoscopies and reclaiming normalcy. ​ Benefit Evidence from Trials' Impact on Patients Dysmenorrhea Reduction: 75% at 6 months ​ Fewer missed workdays Nonmenstrual Pain Relief: 50-60% improvement ​ Enhanced mobility Bleeding Control: 14% bleeding days vs. 24% baseline ​ Improved hygiene, anemia prevention Quality of Life Sustained over 24 weeks ​ Better sleep, relationships Potential Side Effects Common side effects of Eligolux200 mirror hypoestrogenic states: hot flashes, night sweats, headache, and nausea, each affecting about 10% of users. These often lessen as the body adjusts, with 69.5% overall adverse event rate over 24 weeks, mostly mild. Mood changes like irritability or depression occur less commonly, warranting mood monitoring. ​ Bone mineral density (BMD) loss poses a key concern—200mg twice daily causes -1.5% to -2.4% drops at lumbar spine and hip after 6 months, attenuated with calcium/vitamin D or add-back therapy. Rare serious risks include suicidal thoughts, liver enzyme elevations, or allergic reactions like anaphylaxis. Discontinuation due to events stays low at 4-12%. No deaths are linked directly to treatment in trials. ​ Side Effect Category Frequency Management Vasomotor (Hot Flashes) 9.9-10% ​ Lifestyle cooling, dose adjustment Neurologic (Headache) 9.9% ​ Hydration, analgesics Bone Loss Up to 2.4% at 6 months ​ DEXA scans, supplements Mood Changes Less common ​ Psychiatric screening Precautions and Contraindications Avoid Eligolux200 in pregnancy (risk of early loss), known osteoporosis, severe hepatic impairment, or with strong OATP1B1 inhibitors like cyclosporine or gemfibrozil. Women of childbearing age need effective non-hormonal contraception during and 28 days post-therapy, as it impairs recognition of pregnancy via amenorrhea. Not for pediatrics under 18 or geriatrics lacking data. Screen for depression history, liver function, and BMD before starting; monitor quarterly. Drug interactions abound with rifampin (reduces levels) or over 50 others like clarithromycin—inform physicians fully. Breastfeeding lacks safety data; weigh risks. Regular blood/urine tests track efficacy and safety. ​ Dosage Guidelines Initiate Eligolux200 at 150mg daily for milder cases, escalating to 200mg BID for dyspareunia or severe pain, max 6 months at higher dose. Miss a dose? Take promptly unless near the next; never double. Duration caps at 24 months total, with liver-adjusted lower dosing. Pair with add-back for extended use to curb BMD loss. ​ Physicians tailor based on response: 74-77% complete 6-month trials. Swallow intact; no crushing. ​ Clinical Evidence Phase III trials (Elaris EM-I/II) randomized 1689 women, proving both doses superior to placebo for co-primary endpoints of dysmenorrhea and nonmenstrual pain. Open-label extensions to 24 weeks maintained gains. A 12-month study with add-back showed persistent relief and <1% additional BMD loss versus placebo. Real-world use echoes this, positioning Eligolix as first oral GnRH antagonist approved for endometriosis. ​ Versus relugolix, Eligolix offers comparable pelvic pain reduction with adjustable dosing. Indian brands like Eligolux200 align with global standards. ​ Conclusion Eligolux200 transforms endometriosis management, delivering substantial pain relief and functional gains through precise hormonal control. Balancing robust benefits against manageable risks like BMD monitoring empowers women toward symptom-free lives. Consult healthcare providers for personalized integration into care plans.

Other Specifications